Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | AZD2936 |
Trade Name | |
Synonyms | AZD-2936|AZD 2936|Rilvegostomig |
Drug Descriptions |
AZD2936 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-1 (PDCD1), which potentially leads to increased T-lymphocyte antitumor activity, tumor cell killing, and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | PD-L1/PD-1 antibody 101 TIGIT Antibody 18 |
CAS Registry Number | NA |
NCIT ID | C188211 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AZD2936 | AZD2936 | 0 | 1 |
AZD2936 + Capecitabine + Oxaliplatin | AZD2936 Capecitabine Oxaliplatin | 0 | 1 |
AZD2936 + Carboplatin + Datopotamab Deruxtecan | AZD2936 Carboplatin Datopotamab Deruxtecan | 0 | 1 |
AZD2936 + Datopotamab Deruxtecan | AZD2936 Datopotamab Deruxtecan | 0 | 1 |
AZD2936 + Fluorouracil + Leucovorin + Oxaliplatin | AZD2936 Fluorouracil Leucovorin Oxaliplatin | 0 | 1 |